米诺环素对不常见的临床重要革兰氏阴性病原体的活性。
Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.
机构信息
JMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0126421. doi: 10.1128/AAC.01264-21. Epub 2021 Sep 7.
Abstract
The minocycline susceptibility of 3,856 isolates including , , , , and Stenotrophomonas maltophilia from the SENTRY surveillance (2014 to 2019) were analyzed. The susceptibilities of these species (%S) were spp. ( = 411; 92.6%), Burkholderia cepacia species complex ( = 199; 85.9%), spp. ( = 127; 99.2%), spp. ( = 59; 94.9%), Alcaligenes faecalis ( = 42; 88.1%), and S. maltophilia ( = 2,287; 99.5%). These data suggest that minocycline is a useful treatment option for infections caused by unusual Gram-negative pathogens.
摘要
分析了 SENTRY 监测（2014 年至 2019 年）中包括 、 、 、 和嗜麦芽窄食单胞菌的 3856 株分离株的米诺环素敏感性。这些物种的敏感性（%S）为 spp.（ = 411；92.6%）、伯克霍尔德菌属复合种（ = 199；85.9%）、 spp.（ = 127；99.2%）、 spp.（ = 59；94.9%）、粪产碱杆菌（ = 42；88.1%）和嗜麦芽窄食单胞菌（ = 2287；99.5%）。这些数据表明，米诺环素是治疗不常见革兰氏阴性病原体引起的感染的有效治疗选择。
相似文献
1
Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.米诺环素对不常见的临床重要革兰氏阴性病原体的活性。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0126421. doi: 10.1128/AAC.01264-21. Epub 2021 Sep 7.
2
Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.米诺环素对鲍曼不动杆菌-醋酸钙不动杆菌复合体、嗜麦芽窄食单胞菌和洋葱伯克霍尔德菌复合体的美国分离株的活性：来自 SENTRY 抗菌药物监测计划的结果，2014 年至 2018 年。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01154-19. Print 2019 Nov.
3
Drug Resistance in Biofilm and Planktonic Cells of spp., spp., and Clinical Isolates.种、种和种临床分离株生物膜和浮游细胞中的耐药性。
Microb Drug Resist. 2024 Sep;30(9):354-362. doi: 10.1089/mdr.2023.0301. Epub 2024 Jul 19.
4
Trends in the susceptibility of U.S. species complex and isolates to minocycline, 2014-2021.美国 种复合体和 分离株对米诺环素的敏感性趋势。2014-2021 年。
Microbiol Spectr. 2023 Dec 12;11(6):e0198123. doi: 10.1128/spectrum.01981-23. Epub 2023 Nov 3.
5
Antibiofilm and antimicrobial activity of curcumin-chitosan nanocomplexes and trimethoprim-sulfamethoxazole on , and isolates.姜黄素-壳聚糖纳米复合物与甲氧苄啶-磺胺甲恶唑对[具体细菌名称]分离株的抗生物膜和抗菌活性
Expert Rev Anti Infect Ther. 2023 Feb;21(2):213-223. doi: 10.1080/14787210.2023.2166933. Epub 2023 Jan 18.
6
In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.“最后手段”抗生素对不常见非发酵革兰阴性杆菌临床分离株的体外抗菌活性。
Microb Drug Resist. 2012 Aug;18(4):396-401. doi: 10.1089/mdr.2011.0195. Epub 2012 Feb 15.
7
Antimicrobial susceptibility pattern of complex & from North India: Trend over a decade (2007-2016).印度北部 复杂 的抗生素敏感性模式：十年来的趋势（2007-2016）。
Indian J Med Res. 2020 Dec;152(6):656-661. doi: 10.4103/ijmr.IJMR_9_19.
8
Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).米诺环素对来自一项全球监测计划（2013年）的鲍曼不动杆菌复合体、嗜麦芽窄食单胞菌和洋葱伯克霍尔德菌复合体分离株的活性测试。
Diagn Microbiol Infect Dis. 2016 Jul;85(3):352-355. doi: 10.1016/j.diagmicrobio.2016.03.019. Epub 2016 Mar 31.
9
In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.高剂量妥布霉素对囊性纤维化患者分离出的洋葱伯克霍尔德菌复合群和嗜麦芽窄食单胞菌的体外疗效。
Antimicrob Agents Chemother. 2015 Jan;59(1):711-3. doi: 10.1128/AAC.04123-14. Epub 2014 Oct 27.
10
In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020.嗜麦芽窄食单胞菌分离株对相关感染常用抗菌药物的体外药敏结果：来自 2004-2020 年抗菌药物测试领导和监测（ATLAS）计划的数据。
Int J Antimicrob Agents. 2023 Aug;62(2):106878. doi: 10.1016/j.ijantimicag.2023.106878. Epub 2023 Jun 5.
引用本文的文献
1
Clinical challenges treating infections: an update.感染治疗中的临床挑战：最新进展
JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. eCollection 2022 Jun.
2
Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.卡塔尔嗜麦芽窄食单胞菌相关下呼吸道感染的临床与流行病学特征：一项回顾性研究
Cureus. 2022 Mar 17;14(3):e23263. doi: 10.7759/cureus.23263. eCollection 2022 Mar.
3
In Vitro Activity of 22 Antibiotics against Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?22种抗生素对囊性纤维化患者分离株的体外活性。是否有新的治疗选择？
Microorganisms. 2021 Nov 30;9(12):2473. doi: 10.3390/microorganisms9122473.
本文引用的文献
1
Necrotizing fasciitis secondary to lake water inoculation with Aeromonas sobria: A case report.继发于创伤后湖水中嗜水气单胞菌接种的坏死性筋膜炎：病例报告。
Medicine (Baltimore). 2021 Mar 12;100(10):e24981. doi: 10.1097/MD.0000000000024981.
2
What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.碳青霉烯类耐药鲍曼不动杆菌（CRAB）的最佳抗生素治疗策略是什么？韩国的一项多中心研究。
J Glob Antimicrob Resist. 2021 Mar;24:429-439. doi: 10.1016/j.jgar.2021.01.018. Epub 2021 Feb 8.
3
Transmission and Antibiotic Resistance of in Cystic Fibrosis.在囊性纤维化中的传播和抗生素耐药性。
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.02911-20.
4
Clinical and microbiological characteristics of patients colonized or infected by Stenotrophomonas maltophilia : is resistance to sulfamethoxazole/trimethoprim a problem?嗜麦芽窄食单胞菌定植或感染患者的临床和微生物学特征：对磺胺甲恶唑/甲氧苄啶耐药是个问题吗？
Rev Inst Med Trop Sao Paulo. 2020 Dec 7;62:e96. doi: 10.1590/S1678-9946202062096. eCollection 2020.
5
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.替加环素-阿维巴坦和对照药物对来自全球医疗中心的大量当代嗜麦芽寡养单胞菌分离株的抗菌活性研究。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01433-20.
6
Infections and Treatment Options.感染与治疗选择。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01025-20.
7
An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.非乳糖发酵革兰氏阴性少见菌治疗概述。
Pharmacotherapy. 2020 Sep;40(9):936-951. doi: 10.1002/phar.2447. Epub 2020 Aug 14.
8
Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.头孢地尔单独及与左氧氟沙星、米诺环素、多粘菌素B或复方磺胺甲恶唑联合使用对多重耐药嗜麦芽窄食单胞菌的活性。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00559-20.
9
Independent Predictors of Mortality for Aeromonas Necrotizing Fasciitis of Limbs: An 18-year Retrospective Study.四肢气单胞菌坏死性筋膜炎死亡率的独立预测因素：一项 18 年回顾性研究。
Sci Rep. 2020 May 7;10(1):7716. doi: 10.1038/s41598-020-64741-7.
10
Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints.临床和实验室标准协会与抗菌药物敏感性试验欧洲委员会关于黏菌素和多黏菌素 B 临床折点的立场声明。
Clin Infect Dis. 2020 Dec 3;71(9):e523-e529. doi: 10.1093/cid/ciaa121.
Zotero 插件